Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)

AbbVie

Status: Completed

Conditions: Chronic Lymphocytic Leukemia

Study type: Observational

Funder types: Industry

Identifiers

NCT03310190

P16-489

Details and patient eligibility

About

A study to assess the real-life management and use of healthcare resources during the initiation of:

• Venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
• Venetoclax in participants with CLL with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.

Enrollment: 93 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study.
• Has chronic lymphocytic leukemia (CLL) and has received at least one prior therapy.

Exclusion criteria

• Currently participating in an interventional study.
• Has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of CLL.

Trial design

93 participants in 1 patient group

Participants receiving venetoclax

Description:

Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.